Cannabis & Wellness

New clinical trial results for XWRAP® show a significant leap in healing diabetic ulcers, positioning Applied Biologics as a formidable player in a challenging field.

Facing a 'going concern' warning and collapsing revenue, Splash Beverage Group is ditching drinks for drugs. Its investment in Avicanna is a desperate, yet strategic, pivot.

With new AI tools for voice, e-commerce, and in-store sales, Dutchie is betting big on automation. But can technology solve the core challenges of a complex market?

Elysium Health's new Creatine+ isn't just a supplement; it's a signal of a massive structural shift where human vitality becomes a core economic asset.

Lexeo Therapeutics finalizes a pivotal trial for its Friedreich ataxia gene therapy, leveraging a novel trial design and accelerated FDA pathway.

Aussie biotech ENA Respiratory secures crucial US patents for its novel immune modulator, signaling a major strategic move in the multi-billion dollar fight against COPD.

A breakthrough publication identifies a novel protein, LanCL1, as a key target for neuropathic pain, validating a new class of drugs for millions of sufferers.

Sanofi's latest FDA nod for Tzield isn't just a new drug approval; it's a strategic shift from symptom management to disease modification in Type 1 Diabetes.

With a high-yield dividend and perfect rent collection, NewLake Capital signals stability. But is this cannabis REIT a safe haven or just a high-risk reward?

MBX Biosciences' new one-year data for canvuparatide isn't just a clinical win; it's a calculated move to dominate a billion-dollar market left vacant.

A new FDA-designated device aims to filter a deadly protein from the blood of sepsis patients. Can this novel approach finally conquer a global health crisis?

Wellness brands often struggle to turn concepts into viable products. A Utah-based CDMO's new PhD-led center is bridging the gap from science to scale.

Herbs, Etc. just won Superfood of the Year. We explore how a legacy brand uses 57 years of integrity to innovate and thrive in today's crowded market.

Bee You Organics' recent award is more than a win for a small brand. It's a signal that the CPG landscape is being reshaped by waterless innovation.

A $4M grant for a Parkinson's drug isn't just charity; it's a strategic bet on a new era of medicine, where philanthropy acts as the catalyst for the next big cure.

With Thomas Winstanley at the helm, Edibles.com eyes dominance in the wellness-THC space. Can his CPG playbook conquer a booming but volatile market?

With foreign ownership now over 51%, a look at how South Korea's KT&G is attracting giants like BlackRock through performance, policy, and a surprising ESG edge.

Cymbiotika just named co-founder Durana Elmi its creative and experiential chief. It’s more than a title—it’s a blueprint for the future of wellness.

With its pivotal Phase 3 trial complete, Rafael Holdings is on a path to redefine treatment for NPC and transform itself into a commercial-stage biotech.

Sanofi's promising nerve disease drug fails in late-stage trials, leaving vulnerable patients in limbo and highlighting the brutal realities of medical innovation.